2019/03/20 by Lauren Walker, Leonidas Stefanis, Johannes Attems · 1 citation
Medicine · Neuroscience · Psychology · #Parkinson's Disease Mechanisms and Treatments #Nuclear Receptors and Signaling #Neurological disorders and treatments #Dementia with Lewy bodies #Dementia #Parkinson's disease #Lewy body #Disease #Pathological #Neuroscience #Medicine #Alpha-synuclein #Neuropathology #Synucleinopathies #Pathology #Psychology #Psychiatry
paper · pdf · doi:10.1111/jnc.14698
openalex publication_date 2019/03/20 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/29
Lewy body diseases share clinical, pathological, genetic and biochemical signatures, and are regarded as a highly heterogeneous group of neurodegenerative disorders. Inclusive of Parkinson's disease (PD), Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB), controversy still exists as to whether they should be considered as separate disease entities or as part of the same disease continuum. Here we discuss emerging knowledge relating to both clinical, and neuropathological differences and consider current biomarker strategies as we try to improve our diagnostic capabilities and design of disease modifying therapeutics for this group of debilitating neurodegenerative disorders. This article is part of the Special Issue "Synuclein".